JD Supra June 29, 2020
White & Case LLP

The megadeals of 2019 may be off the table for now, but deal activity across healthcare and pharmaceuticals has proven resilient through the COVID-19 crisis

Although pharma, medical and biotech (PMB) M&A deal value for Q1 2020 came in at US$39.3 billion, 78% below the year before, this was primarily due to the outsized US$87.8 billion deal between Bristol-Myers Squibb and Celgene in early 2019.

The strategic importance of well-funded healthcare infrastructure has been emphasized as the COVID-19 virus has spread. The S&P 500 Healthcare Index has lost no value in 2020 and is close to 15% above the value in the previous 12 months. This reflects the value investors see in the long-term prospects for the sector and its...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Investments, Medical Devices, Mergers & Acquisitions / JV, Pharma / Biotech, Trends
In the Pipeline: LifeSpire of Virginia Announces $80M Renovation Plan; Oak Trace Completes Multiphase $112M Campus Redevelopment
Boston Scientific’s $3.7B Axonics buy tops list of medtech M&A in 2024
Digital health venture capital deals stagnate
Ascension continues selling spree
Acadia Executes 3 New Acquisitions, Fueling 2024 Growth Strategy

Share This Article